OncoMatch/Clinical Trials/NCT05247268
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Is NCT05247268 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Megestrol Acetate 160 MG Oral Tablet and Medroxyprogesterone Acetate 500 MG for endometrial neoplasm malignant stage i.
Treatment: Megestrol Acetate 160 MG Oral Tablet · Medroxyprogesterone Acetate 500 MG · Triprorelin Acetate · Letrozole 2.5mg — To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Required: Stage EARLY-STAGE, GRADE I
Grade: I
early-stage endometrial cancer (endometrioid, grade I, without myometrial invasion)
Prior therapy
Cannot have received: hormone treatment
Hormone treatment within 3 months before entering the trial
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify